Repare Therapeutics CEO Segal resigns; CFO Steve Forte becomes CEO effective April 11

Repare Therapeutics Inc.

Lloyd Segal resigns as President, CEO, and Director effective April 11, 2025; not due to disagreement.
Steve Forte (current EVP/CFO) appointed President, CEO, and Director effective same date; will remain CFO.
Sandra Alves promoted to SVP, Chief Accounting Officer; salary raised to CA$350,000; granted 24,500 options and 4,100 RSUs.
Company expects to complete MYTHIC trial enrollment Q2 2025; topline data for POLAR (Q3) and LIONS (Q4) trials.
Company exploring strategic alternatives and partnerships across portfolio, including for lunresertib and camonsertib.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steve Forte

President and Chief Executive Officer

Repare Therapeutics Inc.

Effective: 2025-04-11
Filed: March 31, 2025, 7:59 PM ET

the Board appointed Steve Forte to serve as the Company’s President and Chief Executive Officer in addition to his current role as the Company’s Chief Financial Officer, effective as of the Effective Date.

Departed

Lloyd Segal

President and Chief Executive Officer

Repare Therapeutics Inc.

Effective: 2025-04-11
Successor: Steve Forte
Filed: March 31, 2025, 7:59 PM ET

On March 31, 2025, Lloyd Segal, President and Chief Executive Officer of Repare Therapeutics Inc. (the “ Company ”), notified the board of directors (the “ Board ”) of the Company of his resignation from his positions as President and Chief Executive Officer and as a member of the Board, effective April 11, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Forte was appointed as President and Chief Executive Officer at Repare Therapeutics Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Board appointed Steve Forte to serve as the Company’s President and Chief Executive Officer in addition to his current role as the Company’s Chief Financial Officer, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lloyd Segal resigned as President and Chief Executive Officer at Repare Therapeutics Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On March 31, 2025, Lloyd Segal, President and Chief Executive Officer of Repare Therapeutics Inc. (the “ Company ”), notified the board of directors (the “ Board ”) of the Company of his resignation from his positions as President and Chief Executive Officer and as a member of the Board, effective April 11, 2025

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-25-068880

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.